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allowing exact positioning that is crucial in failing bioprostheses. We
evaluate the acute outcome of degenerated small aortic bioprostheses
treatment with the 23 mm Medtronic CoreValve Evolut R.
METHODS From a total of 560 TAVI performed at our Institute, we
selected 5 consecutive symptomatic patients with degenerated small
aortic bioprostheses showing stenosis, regurgitation or combined
failure. Patients (80  5.5 years) had Logistic EuroSCORE of 29.1  15.8
and STS score of 7.64  6.2. Fast-track general anesthesia with TEE
monitoring was used in all patients. All TAVI were performed by
percutaneous transfemoral access using the 23 mm Medtronic Cor-
eValve Evolut R. After pre-closure with two ProGlide closure devices
(Abbott Vascular), the EnVeo R 14 Fr-equivalent delivery system was
introduced in the common femoral artery and precisely positioned
under ﬂuoroscopic guidance without pre-dilation inside the failed
prostheses. The CoreValve Evolut R was then deployed without
rapid ventricular pacing. Valve recapturing was performed in case of
unsatisfactory positioning with the aim of obtaining minimum pro-
trusion of the CoreValve Evolut R frame below the bioprosthesis
implantation ring.
RESULTS Degenerated stented bioprostheses were one 21-mm Sorin
Mitroﬂow, one 21-mm Carpentier Edwards, one 21-mm Carpentier
Edwards Perimount, and two 19-mm Sorin Mitroﬂow. At MSCT, mean
internal diameter was 17.7 mm. Baseline TTE parameters were: aortic
valve area 0.67  0.17 cm2, peak/mean aortic gradient 69.2  20.3/
44.8  13.4 mmHg; aortic regurgitation was severe in one patient and
moderate in two. After TAVI, aortic valve area increased to 1.34  0.28
cm2, peak/mean aortic gradient decreased to 42.2  12.9/23.8 
6.09 mmHg. Paravalvular leak was mild in three patients and mod-
erate in one. No intra-procedural/in-hospital death, myocardial
infarction, coronary obstruction, stroke and major vascular compli-
cations were observed.
CONCLUSIONS Valve-in-valve treatment of degenerated small aortic
bioprostheses with the CoreValve Evolut R is feasible and safe.
Despite a signiﬁcant increase in aortic area and trans-aortic gradient in
all patients, the mean echocardiographic gradient remained elevated.
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BACKGROUND Self-expanding transcatheter aortic valve replace-
ment (TAVR) is superior to medical therapy for patients with severe
native valve aortic stenosis unsuitable for surgery. Its use in patients
with low-gradient, low output aortic stenosis has not been prospec-
tively studied.
METHODS The CoreValve US Expanded Use Study was a prospective,
non-randomized, single-arm study that evaluated the safety and
effectiveness of TAVR in complex subsets that included extreme risk
patients with low-gradient low output (LGLO) aortic stenosis. LGLO
was deﬁned as Group A: mean gradient < 40 mmHg and peak
velocity < 4 M/sec and resting LVEF  50%, or Group B: mean
gradient < 40 mmHg and peak velocity < 4 M/sec and resting LVEF <
50% who did not augment with dobutamine. These results were
compared with patients enrolled in the Extreme Risk cohort of the US
Pivotal Trial, Group C: mean gradient < 40 mmHg and peak velocity <
4 M/sec and resting LVEF < 50% by resting echo, but who augmented
with dobutamine, and Group D: mean gradient  40 mmHg or peak
velocity  4 M/sec. The primary endpoint was a composite of all-cause
mortality or major stroke rate at 12 months.
RESULTS 189 patients with attempted implant were enrolled between
December 2012 and September 2014 in the Expanded Use Study(Groups A and B). Patients were elderly (81.8  8.7 years), commonly
men (56.6%) and were severely symptomatic (New York Heart Asso-
ciation class III or IV, 89.4%). The STS PROM was 9.9  5.4%. Cor-
eValve diameters included 23 mm (0.5%) 26 mm (22.9%), 29 mm
(39.4%), and 31 mm (37.2%).Group A Group B Group C Group DKM rate (%) or
Mean ± SDN ¼ 136 N ¼ 50 N ¼ 66 N¼ 550Baseline mean
gradient
(mmHg)129.5  4.5 25.1 5.2* 28.8  5.3Ŧ 51.4  12.9ŧBaseline aortic
valve area,
(cm2)10.8  0.2 0.8  0.2 0.7 0.3 0.6  0.2ŧ1 Year all-cause
mortality or
major stroke26.5 27.6 43.9 27.3ŧ1 Year all-cause
mortality22.2 27.6 39.4 25.8ŧ1 Year major
stroke6.7 0.0 11.8Ŧ 4.5ŧN[44 N[16 N[30 N[3351 Year effective
oriﬁce area
(cm2)11.8  0.5 1.9  0.5 1.5  0.4Ŧ 1.7  0.51Site reported data for Groups A and B. Core lab data for Groups C and D. *P<0.05 A vs. B; ŦP<0.05 B vs. C;
ŧP<0.05 C vs. D
CONCLUSIONS The use of CoreValve TAV in LGLO aortic stenosis at
extreme risk for surgery was associated with a low 12-month mortality
rate, and a signiﬁcantly improved aortic valve area that was compa-
rable to the results seen in the Pivotal trial.
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BACKGROUND The combination of severe aortic stenosis (AS) with a
small aortic annulus (SAA) presents a unique challenge to effectively
treat either surgically or percutaneously. The 20mm SAPIEN XT (SXT)
transcatheter heart valve (THV) is currently the smallest of its kind
available for transcatheter aortic valve implantation (TAVI). We report
the initial clinical outcomes and performance of this small THV.
